Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $6.25.

Several equities analysts recently issued reports on HUMA shares. TD Cowen reduced their price objective on Humacyte from $1.50 to $1.25 and set a "buy" rating for the company in a report on Wednesday, June 17th. HC Wainwright upped their target price on Humacyte from $3.00 to $4.00 and gave the company a "buy" rating in a report on Thursday, June 11th. Wall Street Zen upgraded Humacyte from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 1st. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price target on shares of Humacyte in a research note on Tuesday, April 28th. Finally, Benchmark boosted their price objective on shares of Humacyte to $2.00 and gave the stock a "speculative buy" rating in a research report on Monday, June 1st.

Insider Activity

In other Humacyte news, insider Shamik J. Parikh sold 45,887 shares of the company's stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $0.90, for a total value of $41,298.30. Following the transaction, the insider directly owned 272,713 shares in the company, valued at approximately $245,441.70. This represents a 14.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kathleen Sebelius purchased 56,818 shares of Humacyte stock in a transaction on Tuesday, May 19th. The shares were acquired at an average cost of $0.88 per share, for a total transaction of $49,999.84. Following the purchase, the director owned 148,025 shares in the company, valued at approximately $130,262. This trade represents a 62.30% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 3.10% of the company's stock.

Institutional Trading of Humacyte

A number of institutional investors and hedge funds have recently bought and sold shares of HUMA. Geode Capital Management LLC increased its position in shares of Humacyte by 33.4% in the second quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company's stock worth $6,163,000 after acquiring an additional 738,142 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Humacyte by 31.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 70,067 shares of the company's stock valued at $146,000 after acquiring an additional 16,702 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Humacyte by 51.1% during the 2nd quarter. Rhumbline Advisers now owns 177,623 shares of the company's stock valued at $371,000 after acquiring an additional 60,059 shares in the last quarter. Prudential Financial Inc. purchased a new stake in Humacyte during the 2nd quarter worth $28,000. Finally, Marshall Wace LLP boosted its position in Humacyte by 5,308.2% during the 2nd quarter. Marshall Wace LLP now owns 2,639,194 shares of the company's stock worth $5,516,000 after purchasing an additional 2,590,394 shares during the period. Institutional investors and hedge funds own 44.71% of the company's stock.

Humacyte Stock Performance

NASDAQ HUMA opened at $0.74 on Tuesday. The company has a quick ratio of 3.32, a current ratio of 3.93 and a debt-to-equity ratio of 5.46. Humacyte has a 52-week low of $0.55 and a 52-week high of $2.55. The business's 50-day moving average price is $0.84 and its 200 day moving average price is $0.91. The firm has a market cap of $165.29 million, a P/E ratio of -1.31 and a beta of 2.54.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The company had revenue of $0.49 million for the quarter, compared to analysts' expectations of $1.46 million. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. On average, equities research analysts expect that Humacyte will post -0.34 earnings per share for the current year.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company's proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient's own tissue. Humacyte's primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company's lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source